|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the … Tiotropium as Asthma Add-On Treatment Shows Promise |
View full post on asthma – Google News